Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
about
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxinA Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic α-Exosite Binding RegionHuman monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolateIdentification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin AExploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactionsExtraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque originFine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.Isolating and engineering human antibodies using yeast surface display.Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.Yeast surface display for protein engineering and characterizationA decade of yeast surface display technology: where are we now?Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating.Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigensBeyond natural antibodies: the power of in vitro display technologies.Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodiesSlow, reversible, coupled folding and binding of the spectrin tetramerization domain.Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxinSelective targeting of TGF-β activation to treat fibroinflammatory airway diseaseRandom mutagenesis of BoNT/E Hc nanobody to construct a secondary phage-display library.A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.Bi-epitope SPR surfaces: a solution to develop robust immunoassays.Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic ActivityMonoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BEstablishment of cell surface engineering and its development.Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and BA three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoproteinSimultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays.Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
P2860
Q27643327-06CC9155-6480-4B05-9AF1-65AF9C0340ACQ27659624-76EA3603-0726-480A-849D-7CA80D96A416Q28482261-AF1D25A9-CDC8-4C44-87CD-8DAD0B2E733DQ28581589-C1084456-1B8F-4490-B184-24EE96BBB8DBQ28730214-F16B8305-9304-4122-B8FF-66A791984586Q30862040-351866DE-08B8-4F4F-B378-65A6815F5D6FQ31042202-2687835E-7F92-4C6C-ABB4-19E1DB5B9479Q33261279-73E8974A-9051-45E5-BF24-6A3888BE3074Q33269999-68DFBA8F-850A-4EC0-A7ED-D5A389806AA9Q33280948-92BA6BC3-8C87-41D8-91B2-2E00538C7C2BQ33289414-D45EA2CB-B322-42B3-8E33-C02B30BF5081Q33299124-4DB82C4D-2DC2-4AC3-AF60-CF73594A9C61Q33323464-8D273338-0854-4F16-B3D5-71387D86220AQ33361666-BBE24B96-19AE-4AB2-BE75-9B07CD178E21Q33531378-CD8F8F5A-81FB-4CE1-9871-B42039F8903DQ33613925-58EFE4D5-6EDA-4D70-BA24-A42E304AD8EFQ33695432-D0D98DBA-9376-4EF8-9786-224B09785050Q33841864-9EC1FDB4-2977-49CA-8969-DCEE3A65AA00Q33888291-9D6014AA-7EDF-4716-BF62-DDE46EBCD29DQ34048752-5C7E12E8-18A9-413D-8913-11511ED64C58Q34074842-14599872-B952-4906-9692-9CC847E100F2Q34314714-D9E150BC-766C-43D1-A252-59D083661C94Q34404779-A503C7D1-C6B3-4E20-99E8-75D313D23776Q34405413-CACDE090-0B50-42C5-9F32-E67F3FB4E236Q34421055-2E50676F-9B60-4B70-B7B2-B2FAB36BEB2FQ34571717-E4BE3743-7ABF-443D-8960-5A7362149D35Q35125022-CC06EADD-A82F-4A16-AD79-0B3753C81B3CQ35157493-93FF27BF-9905-4F10-B1F6-90DD6C5FBCF3Q35173029-586A9D12-50B1-47E8-AF2B-BEA0E9B0BE33Q35395469-9E627F88-CACC-403F-BF54-35CFA20E2B74Q35746555-D79F1191-AB47-4D9C-A700-87F899991938Q35765577-E47C9C05-0140-41D8-AFE6-072D45143DEEQ35779652-6C693009-1B9A-41B1-A2C7-227CBAFD6B59Q36053204-532894D7-C9BD-4CD3-8B77-203EA575EF42Q36112959-47954EB0-B63E-47A0-A2EC-859223737DA8Q36316488-DA559380-8A03-4EBB-8694-EDCFB41FF81CQ36433965-4796FEE8-DA00-47E3-BD6E-2573BDDD99A4Q36506935-F5E96A0E-EBF1-43EE-A620-EA232FB6FE62Q36661573-E25FCE6A-6F7F-4A56-A7A3-7D7C28C6114BQ36816587-F3C70C28-0EC4-45F7-B794-C857D0F62E8E
P2860
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@ast
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@en
type
label
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@ast
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@en
prefLabel
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@ast
Molecular evolution of antibod ...... f botulinum neurotoxin type A.
@en
P2093
P1476
Molecular evolution of antibod ...... of botulinum neurotoxin type A
@en
P2093
Feldhaus M
Forsyth CM
Garcia-Rodriguez C
P304
P356
10.1016/J.JMB.2005.06.003
P407
P577
2005-08-01T00:00:00Z